Menu
← Oncology Approval Tracker
FDA DECISION ·
Mvasi + chemotherapy
bevacizumab-awwb with indication-specific chemotherapy · Amgen
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds labeled chemotherapy combinations for stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer after initial surgery, for platinum-sensitive recurrence and for platinum-resistant recurrence after no more than two prior chemotherapy regimens.
LAMPGEN ANALYSIS
Why it matters
This supplemental biosimilar action expands use across three distinct ovarian cancer treatment settings.
What research teams should watch
Use the label to confirm combination and maintenance schedules based on recurrence and platinum history.
PRIMARY RECORDS